AR077422A1 - Sales de inhibidores de plk - Google Patents

Sales de inhibidores de plk

Info

Publication number
AR077422A1
AR077422A1 ARP100102683A ARP100102683A AR077422A1 AR 077422 A1 AR077422 A1 AR 077422A1 AR P100102683 A ARP100102683 A AR P100102683A AR P100102683 A ARP100102683 A AR P100102683A AR 077422 A1 AR077422 A1 AR 077422A1
Authority
AR
Argentina
Prior art keywords
salts
counterion
half mole
solvates
hydrates
Prior art date
Application number
ARP100102683A
Other languages
English (en)
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of AR077422A1 publication Critical patent/AR077422A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Formas cristalinas de la base al igual que solvatos e hidratos e estas formas de sales, un proceso para su preparacion, su utilidad en terapia y las composiciones farmacéuticas que las contienen, también son reivindicadas y descritas en la presente solicitud. Reivindicacion 1: Sales del compuesto 937 con la siguiente formula caracterizadas porque son seleccionadas entre L-tartrato, succinato, fosfato, mesilato, maleato, L-malato, clorhidrato, fumarato (medio mol de contraion), fumarato, citrato (medio mol de contraion), bencenosulfonato y L-aspartato (medio mol de contraion), y sus formas cristalinas, solvatos e hidratos.
ARP100102683A 2009-07-29 2010-07-23 Sales de inhibidores de plk AR077422A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09166760 2009-07-29

Publications (1)

Publication Number Publication Date
AR077422A1 true AR077422A1 (es) 2011-08-24

Family

ID=42735665

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102683A AR077422A1 (es) 2009-07-29 2010-07-23 Sales de inhibidores de plk

Country Status (9)

Country Link
US (1) US8648078B2 (es)
EP (1) EP2459196B1 (es)
JP (1) JP5851990B2 (es)
CN (2) CN103626777B (es)
AR (1) AR077422A1 (es)
ES (1) ES2553114T3 (es)
HK (2) HK1166015A1 (es)
TW (1) TW201109334A (es)
WO (1) WO2011012534A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071480A2 (en) * 2007-12-04 2009-06-11 Nerviano Medical Sciences S.R.L. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
CN102382106A (zh) * 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
KR101913441B1 (ko) * 2010-12-17 2018-10-30 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서 치환된 피라졸로-퀴나졸린 유도체
EP2668190B1 (en) * 2011-01-26 2016-08-17 Nerviano Medical Sciences S.r.l. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
WO2012101029A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
WO2012118802A1 (en) 2011-02-28 2012-09-07 Transgenomic, Inc. Kit and method for sequencing a target dna in a mixed population
PT3129374T (pt) 2014-04-07 2019-03-25 Netherlands Translational Res Center B V (5,6-dihidro)pirimido[4,5-e] indolizinas
US9563488B2 (en) 2014-05-29 2017-02-07 Apple Inc. Sharing extension points to allow an application to share content via a sharing extension
EP3840741A4 (en) 2018-08-26 2022-05-04 Cardiff Oncology, Inc. PLK1 TARGET PHOSPHORYLATION STATUS AND TREATMENT OF CANCER WITH PLK1 INHIBITORS
WO2023104178A1 (zh) * 2021-12-10 2023-06-15 山东绿叶制药有限公司 蛋白激酶抑制剂及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582831A (en) * 1984-11-16 1986-04-15 Pfizer Inc. Anti-inflammatory polymorphic monoethanolamine salt of N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound, composition, and method of use therefor
GEP20094664B (en) * 2003-05-22 2009-04-10 Nerviano Medical Sciences Srl Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EA014231B1 (ru) * 2006-02-10 2010-10-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Комбинации, включающие ингибитор cdk и антитело фактора роста или антимитотик
TW200808311A (en) * 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
KR101512284B1 (ko) * 2006-12-21 2015-04-15 네르비아노 메디칼 사이언시스 에스.알.엘. 치환된 피라졸로-퀴나졸린 유도체, 이의 제조방법, 및 키나제 억제제로서의 이의 용도
AR076784A1 (es) * 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico

Also Published As

Publication number Publication date
HK1166015A1 (en) 2012-10-19
CN102470136A (zh) 2012-05-23
CN103626777A (zh) 2014-03-12
US20120157468A1 (en) 2012-06-21
ES2553114T3 (es) 2015-12-04
HK1195773A1 (zh) 2014-11-21
EP2459196B1 (en) 2015-09-09
CN103626777B (zh) 2015-10-21
WO2011012534A1 (en) 2011-02-03
JP2013500299A (ja) 2013-01-07
US8648078B2 (en) 2014-02-11
EP2459196A1 (en) 2012-06-06
CN102470136B (zh) 2013-12-25
JP5851990B2 (ja) 2016-02-03
TW201109334A (en) 2011-03-16

Similar Documents

Publication Publication Date Title
AR077422A1 (es) Sales de inhibidores de plk
AR076433A1 (es) Sales inhibidoras de cdk
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
CO2022006858A2 (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
EA200901609A1 (ru) Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов
RU2008151506A (ru) Новые соли и кристаллические солевые формы производного 2-индолинона
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
NZ547615A (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
CU24461B1 (es) Compuestos útiles para tratar envejecimiento prematuro y en particular progeria
EP4345100A3 (en) Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
CU24099B1 (es) Derivados de sulfonamida para el tratamiento del dolor
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
SV2010003767A (es) Compuestos pirazolicos 436
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
CU20060037A7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
EA201270646A1 (ru) Ингибиторы глюкозилцерамидсинтазы
HK1133012A1 (en) Pyrimidinones as casein kinase ii (ck2) modulators
EA201100035A1 (ru) Производные тиазолилпиперидина
NI201000157A (es) Inhibidores desacetilasas b a base de hidroxamato.
CO2022001853A2 (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr
ECSP10010597A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
BR112017018580A2 (pt) p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal

Legal Events

Date Code Title Description
FB Suspension of granting procedure